Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

ACTG to present data highlighting a new therapeutic for COVID-19 at the virtual IDWeek 2021

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that Teresa H. Evering, M.D., M.S., a co-lead investigator (with Eric S. Daar, M.D.) for BRII-196/BRII-198 in the ACTIV-2 study of Outpatient Monoclonal Antibodies and Other Therapies, will present data for the monoclonal antibody combination at the virtual IDWeek 2021 conference, taking place September 29 – October 3, 2021.

30 Sep 2021

SARS-CoV-2 infection aided by antibody-dependent enhancement

The coronavirus disease 2019 (COVID-19) pandemic has raised concerns about the detrimental effects of antibodies. Antibody-dependent enhancement (ADE) of infection is one of the biggest concerns in terms of not only the antibody reaction to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon reinfection with the virus but also the reaction to COVID-19 vaccines.

30 Sep 2021

Immunocompromised patients show decreased response to SARS-CoV-2 mRNA vaccines

Researchers explore the germinal cell responses in both healthy individuals and kidney transplant patients in their recent study.

29 Sep 2021

Study finds strong evidence of transplacental passage of IgG antibodies following COVID vaccination

In the current study, researchers investigate the transplacental transmission of antibodies in vaccinated pregnant women.

29 Sep 2021

Scientists create new compliance-based model for SARS-CoV-2 transmission

Researchers from Utrecht University have been investigating the interactions between compliance social distance measurements, infection, and vaccination coverage in order to inform public health policy further. A research paper covering their work is available on the medRxiv* preprint server.

28 Sep 2021

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.

27 Sep 2021

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

Researchers in Japan have conducted a study showing that the vaccine developed by Pfizer-BioNTech to protect against coronavirus disease 2019 (COVID-19) seems to be adequately effective against the B.1.621 (mu) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

27 Sep 2021

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Despite the advent of numerous vaccines and the discovery of passive monoclonal antibodies for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there remains an urgent need for definitive therapies for coronavirus disease-2019 (COVID-19) patients.

27 Sep 2021

Study shows prior COVID-19 and vaccination protects elderly against variants

In order to qualify the risk posed to the elderly, researchers from MUSE University in France began to investigate data from nursing homes that had faced outbreaks from variants of concern. Their work can be found on the medRxiv* preprint server while awaiting peer review.

27 Sep 2021

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Japanese scientists created "elite" antibodies that defeat various coronavirus variants even at an extremely low dose through a new method that accelerated the months-long process of finding such extraordinary antibody candidates to just ten days.

27 Sep 2021

Study reveals surfaces of SARS-CoV-2 spike most resistant to antibody escape

A team of international scientists has formed a consortium to map the epitope landscape of a range of therapeutic monoclonal antibodies on the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the scientists characterized the neutralization potency of these antibodies and have investigated how emerging viral variants with spike mutations can impact antibody-mediated neutralization. They have recently published the consortium findings in the journal Science.

27 Sep 2021

Scientists publish a detailed map of where human antibodies bind to SARS-CoV-2

Scientists at La Jolla Institute for Immunology (LJI) have published a detailed map of where human antibodies bind to SARS-CoV-2, a map that was generated by a global collaboration comparing nearly all leading clinical candidates.

24 Sep 2021

No excess mortality during the Delta variant era in US state with high vaccination rates

Researchers have investigated the number of excess deaths during the initial spread of the Delta variant.

24 Sep 2021

A daily pill to treat covid could be just months away, scientists say

Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room.

24 Sep 2021

Monoclonal Antibody News and Research

Further Reading

ACTG to present data highlighting a new therapeutic for COVID-19 at the virtual IDWeek 2021

SARS-CoV-2 infection aided by antibody-dependent enhancement

Immunocompromised patients show decreased response to SARS-CoV-2 mRNA vaccines

Study finds strong evidence of transplacental passage of IgG antibodies following COVID vaccination

Scientists create new compliance-based model for SARS-CoV-2 transmission

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Study shows prior COVID-19 and vaccination protects elderly against variants

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Study reveals surfaces of SARS-CoV-2 spike most resistant to antibody escape

Scientists publish a detailed map of where human antibodies bind to SARS-CoV-2

No excess mortality during the Delta variant era in US state with high vaccination rates

A daily pill to treat covid could be just months away, scientists say

Potential covalent SARS-CoV-2 spike protein inhibitors

The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

Scientists identify potential therapeutic targets to alleviate severe COVID-19 in aged patients

Decline in SARS-CoV-2 neutralizing antibodies and unique cytokine profile in severe COVID-19 patients

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®